Advances in the treatment of Parkinson's disease

被引：240

作者：

Singh, Neha ^{[1
]}

Pillay, Viness ^{[1
]}

Choonara, Yahya E. ^{[1
]}

机构：

[1] Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, Gauteng, South Africa

来源：

PROGRESS IN NEUROBIOLOGY | 2007年 / 81卷 / 01期

关键词：

Parkinson's disease (PD); current therapies; neuroprotective; agents; non-pharmacological treatments; drug delivery; levodopa; nicotine; PD vaccine; cell transplantation;

D O I：

10.1016/j.pneurobio.2006.11.009

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Parkinson's disease (PD) affects one in every 100 persons above the age of 65 years, making it the second most common neurodegenerative disease after Alzheimer's disease. PD is a disease of the central nervous system that leads to severe difficulties with body motions. The currently available therapies aim to improve the functional capacity of the patient for as long as possible; however they do not modify the progression of the neurodegenerative process. The need for newer and more effective agents is consequently receiving a great deal of attention and consequently being subjected to extensive re search. This review concisely compiles the limitations of currently available therapies and the most recent research regarding neuroprotective agents, antioxidants, stem cell research, vaccines and various surgical techniques available and being developed for the management of PD. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：29 / 44

页数：16

共 220 条

[1]

ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23

[2] Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor [J].

Ahn, YH ;

Bensadoun, JC ;

Aebischer, P ;

Zurn, AD ;

Seiger, Å ;

Björklund, A ;

Lindvall, O ;

Wahlberg, L ;

Brundin, P ;

Schierle, GSK .

BRAIN RESEARCH BULLETIN, 2005, 66 (02) :135-142

[3] Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline [J].

Bar Am, O ;

Amit, T ;

Youdim, MBH .

NEUROSCIENCE LETTERS, 2004, 355 (03) :169-172

[4] Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats [J].

Arica, B ;

Kas, HS ;

Moghdam, A ;

Akalan, N ;

Hincal, AA .

JOURNAL OF CONTROLLED RELEASE, 2005, 102 (03) :689-697

[5] Tolcapone and fulminant hepatitis [J].

Assal, F ;

Spahr, L ;

Hadengue, A ;

Rubbici-Brandt, L ;

Burkhard, PR .

LANCET, 1998, 352 (9132) :958-958

[6] A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease [J].

Bartus, RT ;

Emerich, D ;

Snodgrass-Belt, P ;

Fu, K ;

Salzberg-Brenhouse, H ;

Lafreniere, D ;

Novak, L ;

Lo, ES ;

Cooper, T ;

Basile, AS .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :828-835

[7] Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment [J].

Beal, MF .

JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2004, 36 (04) :381-386

[8]

Beal MF, 2003, ANN NY ACAD SCI, V991, P120

[9]

Belluardo N, 2000, ADV RES NEURODEGENER, V8, P227

[10]

Benesová O, 2000, BIOLOGIA, V55, P9

← 1 2 3 4 5 6 7 8 9 10 →